Company intelligence / Profile preview

ABIONYX Pharma

Ownership: Public · ABNX
Employees: ~51
Development stage: Other

Overview

ABIONYX Pharma’s lead asset, CER‑001, has shown positive results in a Phase 2a trial for septic patients at high risk of acute kidney injury. The study met its primary objective with trends toward reduced renal damage and secondary endpoints indicating significant effects on endotoxin removal and endothelial protection. However, full data have not yet been published. Previous development of CER‑001 as a cardiovascular therapy failed to meet endpoints but the company has pivoted to new indications.

Therapeutic areas: NephrologyMetabolic DisordersCardiovascular
Modalities: Recombinant proteinNanoparticleBiologic
Industry: Biotech

Drug pipeline

9 assets

CER-001

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $34.8M
Total revenue: $0
Enterprise value: $628.3M

Beyond the preview

Go deeper on ABIONYX Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABIONYX Pharma.

Explore the full profile